GoodRx Holdings (GDRX) Cash & Current Investments (2019 - 2026)

GoodRx Holdings has reported Cash & Current Investments for 8 years, with the latest figure at $235.7 million in Q1 2026.

• Quarterly Cash & Current Investments fell 21.69% year-over-year to $235.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $235.7 million (down 21.69% YoY) and the FY2025 annual result came in at $261.8 million, down 41.6% from the prior year.
• Cash & Current Investments retreated to $235.7 million in Q1 2026 per GDRX's latest filing, from $261.8 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $845.4 million in Q1 2022 and troughed at $235.7 million in Q1 2026.
• A 5-year average of $549.2 million and a median of $533.3 million in 2024 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments increased 9.07% in 2023, then tumbled 46.69% in 2024.
• Over 5 years, Cash & Current Investments stood at $757.2 million in 2022, then slipped by 11.21% to $672.3 million in 2023, then plunged by 33.31% to $448.3 million in 2024, then tumbled by 41.6% to $261.8 million in 2025, then fell by 9.97% to $235.7 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $235.7 million, $261.8 million, and $273.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.